Burning Rock Biotech Limited (BNR)
NASDAQ: BNR · IEX Real-Time Price · USD
7.55
-0.15 (-1.95%)
At close: May 24, 2024, 4:00 PM
7.57
+0.02 (0.26%)
After-hours: May 24, 2024, 4:00 PM EDT

Company Description

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China.

It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.

The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC.

The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products.

In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model.

Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA.

The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Burning Rock Biotech Limited
Burning Rock Biotech logo
Country China
Founded 2014
IPO Date Jun 12, 2020
Industry Diagnostics & Research
Sector Healthcare
Employees 786
CEO Yusheng Han

Contact Details

Address:
No. 5 Xingdao Ring Road North, International Bio Island
Guangzhou, Guangdong, F4 510005
China
Phone 86 18501641666
Website brbiotech.com

Stock Details

Ticker Symbol BNR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency CNY
IPO Price $16.50
CIK Code 0001792267
CUSIP Number 12233L107
ISIN Number US12233L1070
SIC Code 8071

Key Executives

Name Position
Yusheng Han Founder, Chairman and Chief Executive Officer
Jinxiang Li Chief Financial Officer, Compliance Officer and Director
Dr. Zhihong Zhang Chief Technology Officer and Director
Hao Liu Senior Advisor

Latest SEC Filings

Date Type Title
May 14, 2024 6-K Report of foreign issuer
Apr 29, 2024 20-F Annual and transition report of foreign private issuers
Apr 26, 2024 F-6 POS Post-effective amendments for immediately effective filing
Apr 26, 2024 6-K Report of foreign issuer
Mar 28, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 10, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals